<i id='F0AF571E0A'><strike id='F0AF571E0A'><tt id='F0AF571E0A'><pre id='F0AF571E0A'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa
read more
1:02BryanKohbergerentersthecourtroomforahearingattheLatahCountyCourthouseonJune27,2023,inMoscow,Idah
read more
EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3
read moreFILE-AFloridaA&MhelmetsportstheRattlerslogobeforeanNCAAcollegefootballgameagainstNorthCarolinainChap
